Results · Apr-Jun 2026
Norris Medicines Q1 FY27 results
Sales fell 37% to ₹0.92 crore from ₹1.5 crore in Apr-Jun 2025.
Operating profit was −₹0.28 crore, an operating margin of −30.5% (down 23.6 points from a year ago).
The net loss widened to ₹0.4 crore from ₹0.31 crore.
Against Jan-Mar 2026: sales −34%, swings to a loss.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 0.9 | 1.5 | −37% |
| Operating profit (EBITDA) | -0.3 | -0.1 | n/m |
| Operating margin | −30.5% | −6.9% | −23.6 pts |
| Net profit | -0.4 | -0.3 | loss widens |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.